Prof. Carlos Caldas, MD [7505]
Exactly what does it mean that a tumor sample has a mutation or genomic alteration? Exactly what is being measured? Is the presence of a mutation an “all?or–none” phenomenon or are there additional quantitative levels of characterization ...
Giving the variables associated with reporting on the presence or absence of a mutation in a tumor sample, what other quantifiable elements of an NGS report —allelic fractions, for example— become important for determining the trajectory ...
What is the current role of comprehensive NGS-based panel (CGP) testing for identifying actionable molecular markers across the spectrum of solid tumors? Why is this strategy the optimal approach at the front lines of clinical cancer care? ...
Why is comprehensive characterization of genomic alterations that defines an individual patient’s tumor useful for oncologists and pathologists to guide optimal therapeutic strategies? And what is the value of measuring total mutational ...
What would be the value of combining whole genome testing with RNA sequencing and pathway analysis? (English)
Can you give us a readout on where comprehensive NGS panels have been highly successful in producing improved clinical outcomes linked to molecular marker-directed cancer treatment, and what the challenges are that still remain? (English)
What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE? (English)
How does massively parallel (or ‘next-generation’) DNA sequencing overcome the following practical considerations regarding pathological tumor specimens? (1) Using FFPE specimens, a process that may damage DNA? (2) Accommodating limited ...